---
type: "Symbol"
title: "BridgeBio Oncology Therapeutics (BBOT.US) — Community Discussions"
description: "Community discussions about this stock, including analyst opinions, earnings analysis, and investment strategies from verified financial professionals and active investors."
locale: "en"
url: "https://longbridge.com/en/quote/BBOT.US/topics.md"
symbol: "BBOT.US"
parent: "https://longbridge.com/en/quote/BBOT.US.md"
count: 1
datetime: "2026-03-14T18:12:18.309Z"
locales:
  - [en](https://longbridge.com/en/quote/BBOT.US/topics.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BBOT.US/topics.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BBOT.US/topics.md)
---

# BridgeBio Oncology Therapeutics (BBOT.US) — Community Discussions

### [BBOT develops selective PI3Kα inhibitor BBO-10203 with both anti-tumor and metabolic safety](https://longbridge.com/en/topics/32221461.md)

- Author: [济无咎](https://longbridge.com/en/profiles/9874868.md)
- Datetime: 2025-07-25T02:43:59.000Z
- Comments: 0
- BridgeBio Oncology Therapeutics (BBOT) is a subsidiary of $Bridgebio Pharma(BBIO.US), spun off from its parent company in May 2024. BBOT plans to achieve an independent listing through a SPAC merger w

## References

- [BridgeBio Oncology Therapeutics (BBOT.US)](https://longbridge.com/en/quote/BBOT.US.md)


> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/BBOT.US/topics.md) | [繁體中文](https://longbridge.com/zh-HK/quote/BBOT.US/topics.md)